BRAF and adenoma: In fact, Chen et al. presented preclinical evidence of the potential usefulness of the BRAF-inhibitor vemurafenib in BRAF-mutated primary corticotrope adenoma cells, showing a reduction in ACTH secretion with no difference in cell death rates [42].